CoChat
Sign Up
Cited by 468Regulation of Appetite and ObesityDiabetes Treatment and ManagementPharmacology and Obesity Treatment

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.

Näslund, E, Barkeling, B, King, N, Gutniak, M, Blundell, JE, Holst, JJ, Rössner, S, Hellström, PM·1999·International Journal of Obesity
DOI 10.1038/sj.ijo.0800818
Open this paper in CoChat — free account

Abstract

Background Peripheral administration of glucagon-like peptide-1 (GLP-1) for four hours, to normal weight and obese humans, decreases food intake and suppresses appetite.Objective The aim of this study was to assess the effect of an eight hour infusion of GLP-1 on appetite and energy intake at lunch and dinner in obese subjects.Design Randomised, blinded cross-over design with intravenous infusion of GLP-1 (0.75 pmol x kg(-1) min(-1)) or saline.Subjects Eight obese (body mass index, BMI, 45.5 +/- 2.3 kg/m2) male subjects.Measurements Ad libitum energy intake at lunch (12.00 h) and dinner (16.00 h) after an energy fixed breakfast (2.4 MJ) at 08.00 h. Appetite sensations using visual analogue scales, (VAS) immediately before and after meals and hourly in-between. Blood samples for the analysis of glucose, insulin, C-peptide, GLP-1 and peptide YY. Gastric emptying after breakfast and lunch using a paracetamol absorption technique.Results Hunger ratings were significantly lower with GLP-1 infusion. The summed ad libitum energy intake at lunch and dinner was reduced by 1.7 +/- 0.5 MJ (21 +/- 6%) by GLP-1 infusion (P = 0.01). Gastric emptying was delayed by GLP-1 infusion, and plasma glucose concentrations decreased (baseline: 6.6 +/- 0.35 mmol/L; nadir: 5.3 +/- 0.15 mmol/L). No nausea was recorded during GLP-1 infusion.Conclusions Our results demonstrate that GLP-1 decreases feelings of hunger and reduces energy intake in obese humans. One possible mechanism for this finding might be an increased satiety primarily mediated by gastric vagal afferent signals.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.ijo.0800818

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Cited by

Sorted by citations

Items 301–400 of 466

Related

See all

Metadata

Authors
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P.
Affiliations
  • Danderyds sjukhus (SE)
  • University of Leeds (GB)
ORCID
Venue
International Journal of Obesity
Publisher
Springer Science and Business Media LLC
Published
1999-03
Volume
23
Issue
3
Pages
304-311
ISSN
  • 0307-0565 (ISSN-L)
  • 1476-5497
DOI
10.1038/sj.ijo.0800818
OpenAlex
W2005334239
Cited by
468
References
31
Citations by year
2026: 7 · 2025: 11 · 2024: 10 · 2023: 12 · 2022: 7 · 2021: 10 · 2020: 10 · 2019: 7 · 2018: 12 · 2017: 12 · 2016: 17 · 2015: 22 · 2014: 18 · 2013: 26 · 2012: 25
FWCI
4.67
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • International Journal of Obesity (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
glucagon-like peptide-1, appetite, energy intake, obesity, hunger, gastric emptying, satiety, peptide YY, insulin, glucose, intravenous infusion
MeSH terms
Adult, Appetite, Blood Glucose, C-Peptide, Energy Intake, Double-Blind Method, Eating, Gastric Emptying, Glucagon, Humans, Hunger, Infusions, Intravenous, Insulin, Male, Obesity, Peptide Fragments, Protein Precursors, Body Mass Index, Cross-Over Studies, Peptide YY, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review